Maprotiline_hydrochloride_LCMS_20720_MedChemExpress
MK2-IN-1_hydrochloride_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jul.-24-2017Print Date:Jul.-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :MK2-IN-1 (hydrochloride)Catalog No. :HY-12834ACAS No. :1314118-94-91.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MK2 InhibitorFormula:C27H26Cl2N4O2Molecular Weight:509.43CAS No. :1314118-94-94. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Pink to red (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
NPS-2143_hydrochloride_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:NPS–2143(SB 262470A ) is a selective potent calcium ion–sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroid hormone secretion, respectively.IC50 value: 43 nM(for Ca2+ receptor) [1]Target: CaSRin vitro: NPS 2143, even when tested at much higher concentrations (3 microM), did not affect the activity of a number of other G protein–coupled receptors, including those most structurally homologous to the Ca2+ receptor. NPS 2143 stimulated parathyroid hormone (PTH) secretion from bovine parathyroid cells (EC50 of 41 nM) over a range of extracellular Ca2+ concentrations and reversed the effects of the calcimimetic compound NPS R–467 on [Ca2+]i and on secretion of PTH [1]. The first reported calcilytic compound was NPS 2143, an orally active molecule which elicits rapid, 3– to 4–fold increases in circulating levels of PTH [2].in vivo: When infused intravenously in normal rats, NPS 2143 caused a rapid and large increase in plasma levels of PTH. Ca2+ receptor antagonists are termed calcilytics and NPS 2143 is the first substance (either atomic or molecular) shown to possess such activity [1].When administered together with an antiresorptive agent (estradiol), NPS 2143 causes an increase in trabecular bone volume and bone mineral density in osteopenic rats [2].PROTOCOL (Extracted from published papers and Only for reference)Cell assay [6]The effect of NPS 2143 on Ca2+ receptor–dependent regulation of PTH secretion and cyclic AMP formation was assessed using primary cultures of dissociated bovine parathyroid cells. Following overnight culture, the cells were removed from the flasks by decanting and washed with buffer containing 126 mM NaCl, 4 mM KCl, 1 mM MgSO4, 0.5 mM CaCl2, 0.7 mM K2HPO4/KH2PO4, 20mM Na–HEPES, pH 7.45, 1 mg/ml glucose, and 0.1% bovine serum albumin. Portions (0.2 ml) of this cellular suspension were added to 12– × 75–mm polystyrene tubes with or without NPS 2143 and/or varying concentrations of CaCl2. Incubations (in triplicate) at 37°C for 20 or 30 min were terminated by placing the tubes on ice. Cells were pelleted by centrifugation (500g for 10 min at 4°C) and 0.1 ml of supernatant was immediately assayed for PTH content. A portion of the cellular suspension was left on ice during the incubation period and then processed in parallel with the other tubes. The amount of PTH in the supernatant from the tubes maintained on ice was defined as "basal release" and was subtracted from all other samples. PTH levels were quantified using a rat PTH(1–34)immunoradiometric assay kit, which also detects bovine PTH. For each experiment, results were expressed as picograms of PTH released/106 cells and then normalized to PTH released in 0.5 mM Ca2+. Cell numbers were determined by counting nuclei in a hemocytometer after lysing the cells and staining the nuclei with cresyl violet.Animal administration [6]On the day of study, the rats were infused intravenously (0.1 ml/kg . min) for 120 min with NPS 2143 (0.1 μmol/kg . min) or vehicle, aProduct Name:NPS–2143 (hydrochloride)Cat. No.:HY-10171CAS No.:324523-20-8Molecular Formula:C 24H 26Cl 2N 2O 2Molecular Weight:445.38Target:CaSR Pathway:GPCR/G Protein Solubility:10 mM in DMSO20% aqueous solution of 2–hydroxypropyl–β–cyclodextrin. Blood samples (0.5 ml) were collected before and at various times after the start of the infusion for measurements of plasma levels of PTH and Ca2+. To prevent excessive blood volume loss during the course of the experiment, for each blood sample the erythrocyte pellet was resuspended in an equal volume of normal rat plasma and reinjected. Plasma levels of Ca2+ were measured immediately after collection using a model 634 ionized calcium analyzer. PTH levels were measured using the Immutopics rat PTH(1–34) immunoradiometric assay kit.References:[1]. Huang Y, Breitwieser GE. Rescue of calcium–sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. J Biol Chem. 2007 Mar 30;282(13):9517–25[2]. Marquis, Robert W.; Lago, Amparo M.; Callahan, James F.;Antagonists of the Calcium Receptor. 2. Amino Alcohol–Based Parathyroid Hormone Secretagogues. Journal of Medicinal Chemistry (2009), 52(21), 6599–6605.[3]. Yamamura A, Guo Q, Yamamura H, Zimnicka AM, Pohl NM, Smith KA, Fernandez RA, Zeifman A, Makino A, Dong H, Yuan JX.Enhanced Ca2+–sensing receptor function in idiopathic pulmonary arterial hypertension.Circ Res. 2012 Aug 3;111(4):469–81. Epub 2012 Jun 22.[4]. Nakajima S, Hira T, Hara H.Calcium–sensing receptor mediates dietary peptide–induced CCK secretion in enteroendocrine STC–1 cells.Mol Nutr Food Res. 2012 May;56(5):753–60.[5]. Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, Christopoulos A.Positive and negative allosteric modulators promote biased signaling at the calcium–sensing receptor.Endocrinology. 2012 Mar;153(3):1232–41. Epub 2011 Dec 30.[6]. Nemeth EF, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther. 2001 Oct;299(1):323–31.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
HY-15664_Bivalirudin Trifluoroacetate_MCE
Data SheetBIOLOGICAL ACTIVITY:Bivalirudin Trifluoroacetate is a synthetic 20 residue peptide which reversibly inhibits thrombin.IC50 Value:Target: thrombinin vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor)effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) [1]. In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l [2]. Bivalirudin⁻facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO⁻mediated redox modifications [3].in vivo: The use of bivalirudinprevented further increase in antiheparin/PF4 antibody IgG levels in rats [4]. Three animals in the 500⁻mg/kg/24 h group, and 7 animals in the 2000⁻mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent [5].Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4References:[1]. Ciborowski M, Tomasiak M. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Acta Pol Pharm. 2009 May⁻Jun;66(3):235⁻42.[2]. Xu Y, Wu W, Wang L, Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis. 2013 Apr;24(3):332⁻8.[3]. Rudolph V, Rudolph TK, Schopfer FJ, Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008Nov;327(2):324⁻31.[4]. Zhang R, Huang Y, Zhang M, Bivalirudin Utilization in Rats Undergoing Cardiopulmonary Bypass: Preventing the Increase of Antiheparin/Platelet Factor 4Antibody in Perioperative Period. Clin Appl Thromb Hemost. 2012 Aug 21. [Epub ahead of print][5]. Gleason TG, Chengelis CP, Jackson CB, A 24⁻hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May⁻Jun;22(3):195⁻206.Product Name:Bivalirudin (Trifluoroacetate)Cat. No.:HY-15664CAS No.:128270-60-0Molecular Formula:C 100H 138DF 3N 24O 35Molecular Weight:2295.32Target:ThrombinPathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 31 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USACertificate of AnalysisPHYSICAL AND CHEMICAL PROPERTIESMolecular Formula:C 100H 138DF 3N 24O 35Molecular Weight:2295.32Storage:Powder -20°C 3 years 4°C 2 years In solvent-80°C 6 months -20°C1 monthChemical Structure:ANALYTICAL DATAAppearance:White to off-white (Solid)1H NMR Spectrum:Consistent with structure Purity (NMR):>98.0%Conclusion:The product has been tested and complies with the given specifications.Product Name:Bivalirudin (Trifluoroacetate)Cat. No.:HY-15664CAS No.:128270-60-0Batch No.:09618Chemical Name:L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USASafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Bivalirudin (Trifluoroacetate)Catalog No. :HY-15664CAS No. :128270-60-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:BivalirudinFormula:C100H138DF3N24O35Molecular Weight:2295.32CAS No. :128270-60-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAppm (f1)0.01.02.03.04.05.06.07.08.09.08.1818.1728.1648.1628.1598.0718.0678.0558.0538.0538.0478.0448.0428.0378.0338.0297.9437.9427.4197.4177.4147.3237.3047.2186.9976.6256.6044.4364.2794.2214.2084.2054.1904.1874.1864.1844.1713.7513.3483.3453.3412.9352.9342.9322.9312.9282.9242.6732.6692.6662.6652.5052.5002.4952.1571.8131.8021.7991.7971.7801.7791.7401.7381.7381.7371.7151.7021.6991.6961.6951.68915150214980.8690.815-0.0032.03417.4801.4602.5511.1643.5318.332 5.22410.18210.1064.1899.54021.8987.34610.0471.4155.6736.470Date:1 Jun 2015Document's Title:Catalog No: HY-15664 Batch#09618Spectrum Title:HY_CPK2015-526-09618Frequency (MHz):(f1) 399.741Original Points Count:(f1) 32768Actual Points Count:(f1) 65536Acquisition Time (sec):(f1) 4.0894Spectral Width (ppm):(f1) 20.045 Pulse Program:UnknownTemperature: 20Number of Scans: 8Acq. Date: May 26 2015D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH TFASample ID:CPK2015-526-09618,Catalog No: HY-15664 Batch#09618,DMSO。
离子色谱仪流动注射电导法测定过氧化氢
以 H2 O2 标准溶液的浓度为横坐标，以该条件下 测得 100 mg/L H2 O2 产生的电导响应值为基准，所得 相对电导值为纵坐标，绘制工作曲线（见图 2）。该工
作曲 线 呈 现 良 好 的 线 性，线 性 回 归 方 程 为：! =
0. 0107 " - 0 . 059（4 !：以 100 mg/L H2 O2 样品产生电导 为基准的相对电导值，"：H2 O2 浓度），其相关系数为 0.9996。8 次连续进样所得标准偏差小于 2 . 6% 。在 上述实 验 条 件 下，本 法 可 检 测 的 H2 O2 下 限 为 0 . 5 mg/L。
" 实验部分
"#! 仪器 DX-120 离子色谱仪（美国 DIONEX）；HS20000 软件（杭州英谱科技开发公司）；聚乙烯反应管，内孔
径：1 . 0 mm，外孔径：2 . 0 mm；定量管：25、50 !L；微孔滤膜：孔径 0 . 45 !m。 "#" 实验装置
将 DX-120 离子色谱仪改装后成流动注射流程，详见图 1。
回收率 Recovery （%）
99 . 65
99 . 89
100 . 5
4结 论
本文提出了在离子色谱上用流动注射原理测定过氧化氢的方法，研究了以 H2 SO3 作为载流测定过 氧化氢的最佳条件。该方法与其他方法相比具有方法简便、成本低廉的优势，并充分提高了仪器的利用 率，可用于水处理中过氧化氢含量的监测控制及环境中过氧化氢的监测分析。今后，在本方法基础上， 研究与高效液相色谱柱分离作用结合，使被测物质在柱分离后进行测定，可更好地消除干扰，并有望用
关键词 过氧化氢，亚硫酸，电导法，离子色谱，流动注射
!引 言
cas10347-81-6_Maprotiline HCl_技术参数MedBio
207572-69-8
50mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED12520
Reparixin L-lysine salt
Reparixin L-lysine salt
266359-93-7
10mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED13303
CID 2745687
CID 2745687
264233-05-8
25mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED12532
SRT3190
SRT3190
1204707-73-2
10mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
CRF (human, rat)
86784-80-7
1mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED12494
INCB3344
INCB3344
1262238-11-8
10mM (in 1mL DMSO)
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED12640
Fluticasone propionate
Shimadzu - LCMS-2020 Vacuum System Main Unit ESI P
6 month Service X
X X X
X X X X X X X X
36 month Service 48 month Service 60 month Service
X X
X X X
X X X
Note: These time frames are only suggestions and items may need to be replaced more frequently depending on sample throughput and use
X
Note: These time frames are only suggestions and items may need to be replaced more frequently depending on sample throughput and use
Shop online ~ or call Shimadzu at 800-477-1227
Shop online ~ or call Shimadzu at 800-477-1227
2
LCMS-8030/8040
Triple Quadrupole Mass Spectrometer
LCMS-8030
LCMS-8040
Vacuum System
Main Unit
SSI-LCMS-11-2015
Liquid Chromatography Mass Spectrometry
LCMS Consumables
LCMS-2020
Single Quadrupole Mass Spectrometer
Inspection/Maintenance Schedule
Dasatinib_hydrochloride_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Dasatinib hydrochloride is a potent and dual Abl WT /Src inhibitor IC 50 of 0.6 nM/0.8 nM respectively; also inhibits c–Kit WT /c–Kit D816V with IC 50 of 79 nM/37 nM.IC50 & Target: IC50: 0.6 nM/0.8 nM (Abl WT /Src)[1]IC50: 79 nM/37 nM (c–Kit WT /c–Kit D816V )[2]In Vitro: Dasatinib potently inhibits wild–type Abl kinase and all mutants except T315I over a narrow range (IC 50≤1.7 nM). Dasatinib (IC 50: 0.8 nM) displays 325–fold greater potency compared with Imatinib against cells expressing wild–type Bcr–Abl in Ba/F3 cells [1].In Vivo: Daily treatment with Dasatinib (50 mg/kg) is initiated on day 10. Using this approach, a significant inhibition of BCPAP orthotopic tumor growth is observed 6 days after treatment (day 16, P=0.014), which is sustained through days 23 and 29(P=0.0003), compared with vehicle–treated mice [3]. Metabolism studies of Dasatinib (50 mg/kg) in rat suggested that Dasatinib is the major circulating component, whereas multiple metabolites contributed to the remaining 40–60% of the sample radioactivity at 4 h post dose [4].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Kinase assays using wild–type and mutant glutathione S–transferase (GST)–Abl fusion proteins (c–Abl amino acids 220–498) are done with minor alterations. GST–Abl fusion proteins are released from glutathione–Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST–Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1–hour incubation at 30°C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST–Abl kinase to dephosphorylated GST–Abl kinase is routinely done using phosphotyrosine–specific antibody 4G10 to confirm complete (>95%)dephosphorylation of tyrosine residues and c–Abl antibody CST 2862 to confirm equal loading of GST–Abl kinase. The inhibitor concentration ranges for IC 50 determinations are 0 to 5,000 nM (Imatinib and AMN107) or 0 to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST–Src kinase and GST–Lyn kinase.Cell Assay: Dasatinib is dissolved in DMSO (10 mM) and stored, and then diluted with appropriate media before use [1].[1]Ba/F3 cell lines are plated in triplicate and incubated with escalating concentrations of Imatinib, AMN107, or Dasatinib for 72 hours.Proliferation is measured using a methanethiosulfonate–based viability assay (CellTiter96 Aqueous One Solution Reagent). IC 50 and IC 90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges for IC 50 and IC 90determinations are 0 to 2,000 nM (Imatinib and AMN107) or 0 to 32 nM (Dasatinib). The imatinibconcentration range is extended to 6,400 nM for mutants with IC 50>2,000 nM. The Dasatinib concentration range is extended to 200Product Name:Dasatinib (hydrochloride)Cat. No.:HY-10181A CAS No.:854001-07-3Molecular Formula:C 22H 27Cl 2N 7O 2S Molecular Weight:524.47Target:Src; Bcr–Abl; Autophagy Pathway:Protein Tyrosine Kinase/RTK; Protein Tyrosine Kinase/RTK;Autophagy Solubility:DMSO: 15 mg/mLnM for mutant T315I.Animal Administration: Dasatinib is prepared in 80 mM sodium citrate buffer, pH 3.0 (Mice)[3].Dasatinib is prepared in 0.5% methylcellulose (Rat)[4].[3][4]Mice[3]Male athymic nude mice (25 grams; 5–week old) are used. Dasatinib (50 mg/kg) is prepared for daily oral gavage (5 d/wk) in 80 mM sodium citrate buffer, pH 3.0. For the orthotopic murine model, mice are randomized on day 10 based on bioluminescence activity to receive drug or vehicle. In the metastatic murine model, mice receives dasatinib or vehicle, as described earlier, starting 2 days before intracardiac injection (pretreatment), or on day 11 following randomization (posttreatment).Rat[4]Dasatinib is dosed to male Wistar–Han (WH) rats at 50 mg/kg orally in 0.5% methylcellulose. The automated rat blood collection device is programmed to collect 200 μL of blood at predetermined intervals. At each time point, the accusampler is programmed to directly spot 20 μL of blood twice (two spots) onto the DBS card. The remaining 160 μL of liquid blood is collected into sodium EDTA–containing tubes. Plasma samples are obtained after immediate centrifugation of blood at 11,000 rpm for 5 min. The plasma samples are stored at -80°C until analyses. The DBS samples are dried under room temperature for a minimum of 2 h and stored in a plastic bag in the dessicator until sample analysis.References:[1]. O'Hare T, et al. In vitro activity of Bcr–Abl inhibitors AMN107 and BMS–354825 against clinically relevant imatinib–resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500–5.[2]. Shah NP, et al. Dasatinib (BMS–354825) inhibits KITD816V, an imatinib–resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286–91.[3]. Chan CM, et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 1;18(13):3580–91.[4]. Shen Z, et al. Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection. J Pharm Biomed Anal. 2012Aug–Sep;67–68:92–7.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
美罗培南三水化合物JP日本药典标准翻译
美罗培南三水化合物按无水物计算，美罗培南三水化合物的含量不得低于900μg/mg。
美罗培南三水化合物的量用美罗培南（C17H25N3O5S：383.46）表示。
性状：美罗培南三水化合物呈白色至微黄色结晶性粉末。
本品微溶于水，几乎不溶于乙醇（95）。
鉴别：（1）将0.01g美罗培南溶于2mL水中，加3mL盐酸羟铵乙醇试剂，静置5分钟，再加1mL酸性硫酸铵铁试液（Ⅲ），摇匀：红棕色沉淀。
（2）按紫外分光光度法测定美罗培南三水化合物和美罗培南三水化合物标准品（3→100000）的吸收光谱图，比较图谱：相同波长下两者的吸光度相似。
（3）按红外光谱法，将美罗培南三水化合物和美罗培南三水化合物标准品用溴化钾制成圆片状，记录红外光谱图，比较图谱：在相同的波数下两者的透光率相似。
旋光度[]20α：-17—-21°（称取0.22g（按无水物计算）溶于50ml水D中，100mm）。
pH将0.2g的美罗培南三水化合物溶于20ml水中：pH为4.0～6.0。
纯度（1）溶液的澄清度和颜色—另有规定（2）重金属—将2.0g美罗培南三水化合物根据方法2进行测试。
对照溶液中加入2.0ml标准铅溶液（不得过10ppm）。
（3）有关物质—另有规定。
水分11.4%～13.4%（0.15g，按库仑滴定法在140℃蒸发温度条件下用配有水分蒸发设备的滴定仪测定。
）炽灼残渣 另有规定细菌内毒素 ＜0.12EU/mg （含量）。
含量 精密称取0.05g （含量）美罗培南和美罗培南标准品，精确加入10ml 内部标准溶液溶解，加pH5.0磷酸三乙胺缓冲液定容至100ml,分别作为样品溶液和对照品溶液。
根据液相色谱条件分别进样5μL 样品溶液和对照品溶液进行测试，计算出美罗培南峰面积Q T 和美罗培南标准品峰面积Q S 的比值。
美罗培南（C 17H 25N 3O 5S ）的量（μg 含量）=美罗培南三水化合物标准品的量（mg 含量）×ST Q Q ×1000 内标溶液—将乙醇苯甲基和磷酸三乙胺缓冲液（pH5.0）按1：300混合。